AlphaCentric Advisors’s Agios Pharmaceuticals AGIO Stock Holding History

AlphaCentric Advisors’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$526K	Buy	14,173 +202	+1%	+$6.13K	0.45%	77
2026 Q1	$473K	Buy	13,971 +830	+6%	+$23.5K	0.47%	67
2025 Q4	$358K	Buy	+13,141	New	+$461K	0.36%	91
2024 Q4	$202K	Buy	+6,140	New	+$288K	0.2%	118
2022 Q4	–	Sell	-15,000	Closed	-$424K	–	168
2022 Q3	$424K	Buy	+15,000	New	+$402K	0.44%	64
2021 Q4	$378K	Buy	+11,500	New	+$463K	0.11%	74

Other funds holding AGIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

AlphaCentric Advisors's AGIO Position: Q2 2026 in Review

AlphaCentric Advisors increased its Agios Pharmaceuticals (AGIO) stake by 1.4% in Q2 2026, buying an estimated $6.13K and bringing the position to 14,173 shares worth $526K. The position accounts for 0.45% of the portfolio, ranked #77.

AlphaCentric Advisors first reported a position in AGIO in Q4 2021 and has held it in 6 quarters since. 239 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

AlphaCentric Advisors held 14,173 shares of Agios Pharmaceuticals worth $526K as of Q2 2026.
AlphaCentric Advisors bought 202 Agios Pharmaceuticals shares in Q2 2026, an estimated $6.13K.
Agios Pharmaceuticals made up 0.45% of AlphaCentric Advisors's portfolio in Q2 2026, its #77 holding.
AlphaCentric Advisors first reported a position in Agios Pharmaceuticals in Q4 2021 and has held it in 6 quarters since.
239 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.